46 related articles for article (PubMed ID: 32417221)
1. ASO Author Reflections: Simplifying the Fundamentals of Gastric Neuroendocrine Tumor Management.
Sok C; Shah MM
Ann Surg Oncol; 2024 Mar; 31(3):1519-1520. PubMed ID: 38123732
[No Abstract] [Full Text] [Related]
2. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review.
Pellat A; Coriat R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492939
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.
Asa SL; La Rosa S; Basturk O; Adsay V; Minnetti M; Grossman AB
Endocr Pathol; 2021 Mar; 32(1):169-191. PubMed ID: 33459926
[TBL] [Abstract][Full Text] [Related]
4. Update on gastroenteropancreatic neuroendocrine tumors.
Andreasi V; Partelli S; Muffatti F; Manzoni MF; Capurso G; Falconi M
Dig Liver Dis; 2021 Feb; 53(2):171-182. PubMed ID: 32912771
[TBL] [Abstract][Full Text] [Related]
5. Gastric neuroendocrine tumor: A practical literature review.
Roberto GA; Rodrigues CMB; Peixoto RD; Younes RN
World J Gastrointest Oncol; 2020 Aug; 12(8):850-856. PubMed ID: 32879663
[TBL] [Abstract][Full Text] [Related]
6. Surgery for GEP-NETs.
Knigge U; Hansen CP
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):819-31. PubMed ID: 23582921
[TBL] [Abstract][Full Text] [Related]
7. Management of gastro-entero-pancreatic neuroendocrine tumours (GEP NET): an introduction.
Van Hootegem P; Borbath I; Verslype C
Acta Gastroenterol Belg; 2009; 72(1):27-8. PubMed ID: 19402367
[No Abstract] [Full Text] [Related]
8. Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?
Pusceddu S; Buzzoni R; De Braud F
Ann Oncol; 2013 May; 24(5):1415-6. PubMed ID: 23493138
[No Abstract] [Full Text] [Related]
9. [Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET)].
Aoki T; Kokudo N
Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2272-9. PubMed ID: 25482902
[No Abstract] [Full Text] [Related]
10. GEP-NET: Knowledge gaps in the recent ESMO Guidelines.
Jain A; Yip D
Ann Oncol; 2020 Sep; 31(9):1260-1261. PubMed ID: 32417221
[No Abstract] [Full Text] [Related]
11. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
